{
    "clinical_study": {
        "@rank": "120862", 
        "arm_group": [
            {
                "arm_group_label": "Teste", 
                "arm_group_type": "Experimental", 
                "description": "Enoxalow (Heparin, Low-Molecular-Weight) - Blau Farmac\u00eautica S/A."
            }, 
            {
                "arm_group_label": "Comparador", 
                "arm_group_type": "Active Comparator", 
                "description": "Clexane (Heparin, Low-Molecular-Weight)- Sanofi-Aventis"
            }
        ], 
        "brief_summary": {
            "textblock": "The hypothesis of this trial is that the test drug (Enoxalow\u00ae - T) pharmacodynamics\n      parameters are similar to the comparator drug (Clexane\u00ae - C) in healthy subjects following\n      administration of single intravenous dose. The objective of this randomized, crossover,\n      clinical trial is to evaluate the pharmacodynamic profile of the test drug Enoxalow\u00ae - T\n      produced by Blau Farmac\u00eautica, compared to the comparator drug Clexane\u00ae, produced by\n      Sanofi-Aventis, by determining pharmacodynamic activities (including anti FXa and\n      anti-FIIa), as surrogate markers for their circulating concentrations of the drug."
        }, 
        "brief_title": "Pharmacodynamics Study of Enoxalow Compared to Clexane in Healthy Subjects After Intravenous Administration", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "In addition other pharmacodynamic tests such as Tissue Factor Pathway Inhibitor (TFPI)\n      activity, as well as the ratio of anti-FXa and anti-FIIa activity will be compared as\n      secundary obectives."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Agree to all the purposes of the study by signing and dating the Informed Consent;\n\n          -  Male, aged between 18 and 55 years, clinically healthy;\n\n          -  BMI between 18.5 and 30;\n\n        Exclusion Criteria:\n\n          -  Participation in clinical trials in the 12 months preceding the trial;\n\n          -  Presence of pulmonary, cardiovascular, neurological, endocrine, gastrointestinal,\n             genitourinary or other systems diseases;\n\n          -  Acute disease in the period of 07 days before the beginning of the practical phase\n             (administration of the drug) of the study;\n\n          -  Chronic administration of medications for hypertension, diabetes or any other disease\n             that requires continuous use of any drug;\n\n          -  Hemoglobin <13 g/dL;\n\n          -  Continuous use of oral anticoagulants, platelet inhibitors or anti-inflammatory\n             drugs;\n\n          -  Use of medications that interact with enoxaparin;\n\n          -  History of gastrointestinal bleeding, deep vein thrombosis or pulmonary embolism that\n             may interfere with the clinical outcome of the study;\n\n          -  History of coagulopathy and bleeding diathesis;\n\n          -  Presence of changes in physical examination suggestive of coagulation disorders\n             (bruising, petechiae, or bruising);\n\n          -  Body weight < 45 kg or > 100 kg;\n\n          -  Absolute platelet count below 100 x 109 / L;\n\n          -  History of chronic bleeding;\n\n          -  History of acute haemorrhage in the past 30 days;\n\n          -  History of sensitivity to mammalian-derived biological products, albumin or any\n             component of the formulation;\n\n          -  History of allergy or Steven Johnson disease;\n\n          -  Current or previous history (under 12 months) use of illicit drugs and tobacco;\n\n          -  History of alcohol abuse, current or previous (within 12 months);\n\n          -  At the discretion of the Principal Investigator of the study."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01692171", 
            "org_study_id": "ENOBLA0612IV-I", 
            "secondary_id": "Vers\u00e3o 01 datada de 20.06.2012"
        }, 
        "intervention": {
            "arm_group_label": [
                "Teste", 
                "Comparador"
            ], 
            "description": "single intravenous administration of 3mg/Kg of the test drug and the comparator drug, according to randomization, in a crossover design, each administration separated by 6 days of washout.", 
            "intervention_name": "Heparin, Low-Molecular-Weight", 
            "intervention_type": "Drug", 
            "other_name": [
                "Clexane", 
                "Enoxalow"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Heparin", 
                "Heparin, Low-Molecular-Weight", 
                "Dalteparin", 
                "Enoxaparin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Subjects", 
        "lastchanged_date": "September 24, 2012", 
        "location": {
            "contact": {
                "email": "alexandre@lalclinica.com.br", 
                "last_name": "Alexandre Frederico", 
                "phone": "+55 11 3871-6399"
            }, 
            "facility": {
                "address": {
                    "city": "Valinhos", 
                    "country": "Brazil", 
                    "state": "Sao Paulo", 
                    "zip": "13276-245"
                }, 
                "name": "LAL Clinica"
            }, 
            "investigator": {
                "last_name": "Alexandre Frederico", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "2", 
        "official_title": "Pharmacodynamics Study of Enoxalow, Produced by Blau Farmac\u00eautica S/A, Compared to Clexane, Produced by Sanofi-Aventis Farmac\u00eautica Ltda, in Healthy Subjects After Intravenous Administration.", 
        "overall_contact": {
            "email": "alexandre@lalclinica.com.br", 
            "last_name": "Alexandre Frederico", 
            "phone": "+55 19 38716399"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Brazil: National Health Surveillance Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "anti-FXa", 
                "safety_issue": "Yes", 
                "time_frame": "0; 0:10; 0:20; 0:30; 0:40 0:50; 1; 1:30; 2; 2:30; 3; 3:30; 4; 5; 6; 8; 10; 12; 16 e 24  hours after grug administration"
            }, 
            {
                "measure": "anti-FIIa activity", 
                "safety_issue": "Yes", 
                "time_frame": "0; 0:10; 0:20; 0:30; 0:40 0:50; 1; 1:30; 2; 2:30; 3; 3:30; 4; 5; 6; 8; 10; 12; 16 e 24 hours after grug administration"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01692171"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Tissue Factor Pathway Inhibitor (TFPI)", 
                "safety_issue": "Yes", 
                "time_frame": "0; 0:10; 0:20; 0:30; 0:40 0:50; 1; 1:30; 2; 2:30; 3; 3:30; 4; 5; 6; 8; 10; 12; 16 e 24 hours after grug administration"
            }, 
            {
                "measure": "ratio of anti-FXa and anti-FIIa activity", 
                "safety_issue": "Yes", 
                "time_frame": "0; 0:10; 0:20; 0:30; 0:40 0:50; 1; 1:30; 2; 2:30; 3; 3:30; 4; 5; 6; 8; 10; 12; 16 e 24 hours after grug administration"
            }
        ], 
        "source": "L.A.L Clinica Pesquisa e Desenvolvimento Ltda.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "L.A.L Clinica Pesquisa e Desenvolvimento Ltda.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}